Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

But even without that, Amgen's top line increased by 8% compared to the year-ago period organically, a solid performance.

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

阿斯利康和安进公司联合公布了Tezspire用于治疗慢性鼻窦炎伴鼻息肉的3期试验的主要结果，显示该治疗显著缩小了患者的鼻息肉大小，并减轻了鼻塞症状。试验的积极结果表明该药有望成为这种疾病的新治疗选择。 慢性鼻窦炎伴鼻息肉是一种复杂的炎症性疾病 ...

WILMINGTON, Del., November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo Positive high-level results from the ...

在最新的试验结果中，Tezspire治疗组展现出了统计学和临床意义上显著的改善，这标志着在慢性鼻窦炎及鼻息肉治疗方法上的一大突破。这项研究结果为进一步的临床应用奠定了基础，同时也为医务人员提供了新的武器，以更有效地帮助患者。